Relafen Settlement Affirms Need For Tort Reform, GSK's Garnier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Wholesalers maintain they were overcharged for Relafen while GSK patent litigation prevented generics from entering the market. GSK says wholesalers can earn higher margins on branded products.
You may also be interested in...
Tort Reform Needed To Relieve “Chronic Pain” Of Litigation, GSK Says
Legal costs within the pharmaceutical industry are becoming a "chronic pain" that can only be addressed through comprehensive tort reform, GlaxoSmithKline CEO J.P. Garnier said July 27.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.